ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
10 announcements with these filters
Aarey Drugs schedules a 14 November 2026 board meeting to approve unaudited half-year results. Trading window stays closed until 48 hours after results.
Aarey Drugs & Pharmaceuticals Ltd filed its quarterly shareholding pattern as of September 30, 2026, in compliance with SEBI regulations.
Aarey Drugs approved allotment of 1,150,000 equity shares from warrant conversion at ₹47.85 each, receiving ₹5.50 Crore. Issued capital rises to 31,874,303 shares.
Promoter and promoter group of Aarey Drugs & Pharmaceuticals Ltd acquired 23.70 lakh shares following the conversion of warrants. The acquisition increased their stake by 4.81%.
Aarey Drugs allotted equity shares to promoters following the conversion of 23,40,000 warrants. This capital structure change increases the promoters' equity stake in the company.
Aarey Drugs & Pharmaceuticals Ltd. held its 36th Annual General Meeting on September 30, 2026, to conduct business including financial statement adoption and director re-appointment.
Aarey Drugs & Pharmaceuticals Ltd approved the allotment of 11,50,000 equity shares following the conversion of warrants. The allotment aggregate value is Rs. 7.34 Crore.
Aarey Drugs & Pharmaceuticals Ltd filed its quarterly shareholding pattern. This is a routine regulatory compliance disclosure regarding the company's equity distribution.
Aarey Drugs approved the Board Report and called its 36th Annual General Meeting to be held on September 30, 2026.
Aarey Drugs & Pharmaceuticals Ltd reported revenue from operations of ₹44.6 Cr (-56.4% YoY) and net profit of ₹1 Cr (-28.6% YoY) for Q1 FY27.